<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110417</url>
  </required_header>
  <id_info>
    <org_study_id>V4.0 28July2021</org_study_id>
    <nct_id>NCT05110417</nct_id>
  </id_info>
  <brief_title>Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine</brief_title>
  <official_title>Pilot Study of the Efficacy of Pyridostigmine for Reversal of Post Injection Dysphonia Following Botulinum Neurotoxin Laryngeal Chemo-Denervation in Spasmodic Dysphonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of pyridostigmine (Mestinon) on patient&#xD;
      vocal outcomes after undergoing laryngeal botulinum neurotoxin (BoNT) injections, which is a&#xD;
      standard treatment for spasmodic dysphonia. Pyridostigmine (Mestinon) has been used for&#xD;
      treatment of BoNT overdose, and it is our hope that it will be beneficial in the management&#xD;
      of post BoNT breathy phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 10 subjects and will involve 1 clinic visit with two sessions over 2&#xD;
      hours.&#xD;
&#xD;
      Participants' voices will then be analyzed via sentence/passage reading, sustained vowel&#xD;
      holding, maximum phonation time, as well as subjective ratings of effort. During the second&#xD;
      clinic visit, participants will then be administered one 60mg tablet of pyridostigmine&#xD;
      (Mestinon) orally, and asked to return to the clinic in 2 hours, when Mestinon has reached&#xD;
      peak plasma concentration. Upon returning, participants will repeat the vocal analysis and&#xD;
      results will be evaluated for any change in outcome.&#xD;
&#xD;
      Patients who are pregnant, lactating, or have kidney or heart disease should not participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot study so all 10 participants will be assigned to the pyridostigmine (Mestinon) treatment arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rainbow Passage Reading Pre- and Post-Pyridostigmine (Mestinon)</measure>
    <time_frame>15 Minutes</time_frame>
    <description>This pilot study aims to evaluate the efficacy of pyridostigmine (Mestinon) to improve vocal outcomes following laryngeal chemo-denervation with botulinum neurotoxin injection which is a standard of care treatment of adductor spasmodic dysphonia. One of the outcome measures used will be the Rainbow Passage reading. A comparison between pre-pyridostigmine reading and post-pyridostigmine reading will be performed to meet this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAPE-V Pre- and Post-Pyridostigmine (Mestinon)</measure>
    <time_frame>15 Minutes</time_frame>
    <description>This pilot study aims to evaluate the efficacy of pyridostigmine (Mestinon) to improve vocal outcomes following laryngeal chemo-denervation with botulinum neurotoxin injection which is a standard of care treatment of adductor spasmodic dysphonia. Another outcome measurement used will be the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V). A comparison between the pre-pyridostigmine evaluation of the CAPE-V and post-pyridostigmine evaluation of the CAPE-V will be performed to meet this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glottal Function Index Pre- and Post-Pyridostigmine (Mestinon)</measure>
    <time_frame>15 Minutes</time_frame>
    <description>This pilot study aims to evaluate the efficacy of pyridostigmine (Mestinon) to improve vocal outcomes following laryngeal chemo-denervation with botulinum neurotoxin injection which is a standard of care treatment of adductor spasmodic dysphonia. Another primary outcome measure being assessed is the glottal function index (GFI). A comparison between the pre-pyridostigmine GFI and post-pyridostigmine GFI will be performed to meet this outcome measure. Score is ranked from 0 to 5. The lower the GFI score indicates fewer problems/effort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adapted Borg Scale Pre- and Post-Pyridostigmine (Mestinon)</measure>
    <time_frame>15 Minutes</time_frame>
    <description>This pilot study aims to evaluate the efficacy of pyridostigmine (Mestinon) to improve vocal outcomes following laryngeal chemo-denervation with botulinum neurotoxin injection which is a standard of care treatment of adductor spasmodic dysphonia. Another primary outcome measure being assessed is the adapted Borg scale. A comparison between the pre-pyridostigmine scale rating and the post-pyridostigmine scale rating will be performed to meet this outcome measure. The scale is ranked from 0 to 10. The higher the number indicates more effort in the tasks while a lower number indicates less effort.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dysphonia, Spastic</condition>
  <condition>Dysphonia</condition>
  <condition>Laryngeal Dystonia</condition>
  <arm_group>
    <arm_group_label>Pyridostigmine (Mestinon)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyridostigmine (Mestinon) will be assigned to patients in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine Bromide 60 Milligrams (mg)</intervention_name>
    <description>One tablet will be provided to patients during the second visit.</description>
    <arm_group_label>Pyridostigmine (Mestinon)</arm_group_label>
    <other_name>Amneal Pharmaceuticals Pvt. Ltd.</other_name>
    <other_name>Serial Number: 1000462308</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females Aged 21-100&#xD;
&#xD;
          -  Scheduled for Botulinum Neurotoxin (BoNT) Treatment for Spasmodic Dysphonia (SD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are Pregnant or Lactating&#xD;
&#xD;
          -  Subjects with Compromised Renal or Cardiac Function&#xD;
&#xD;
          -  Subjects with Spasmodic Dysphonia with Superimposed Vocal Tremor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Rubinstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Addy Tham, MS</last_name>
    <phone>757.388.6264</phone>
    <email>thama@evms.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Stone, RN</last_name>
    <phone>757.388.6238</phone>
    <email>stonelj@evms.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Virginia Medical School Ear, Nose, and Throat Surgeons</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Addy Tham, MS</last_name>
      <phone>757-388-6264</phone>
      <email>thama@evms.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Stone, RN</last_name>
      <phone>757.388.6238</phone>
      <email>stonelj@evms.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Rubinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Sinacori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Michalek, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Virginia Medical School</investigator_affiliation>
    <investigator_full_name>Benjamin J Rubinstein</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>pyridostigmine</keyword>
  <keyword>dysphonia</keyword>
  <keyword>spasmodic dysphonia</keyword>
  <keyword>Mestinon</keyword>
  <keyword>botulinum neurotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
    <mesh_term>Dystonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

